---
schema_version: "secwatch.filing_event.v1"
accession: "0001599298-22-000109"
form_type: "8-K"
ticker: "SMMT"
cik: "0001599298"
company_name: "Summit Therapeutics Inc."
filed_at: "2022-10-03T23:59:59+00:00"
generated_at: "2026-06-23T05:58:17.045925+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Summit Therapeutics appoints Dr. Robert Booth to Board of Directors; Dr. Urte Gayko resigns from Board

## Summary
- Dr. Robert Booth appointed to Board effective September 28, 2022; will join Nominating and Corporate Governance Committee.
- Dr. Booth initiated the BTK inhibitor program at Celera Genomics that led to Pharmacyclics' blockbuster drug Imbruvica (ibrutinib).
- Dr. Booth received stock option grant per non-employee director compensation policy and standard indemnification agreement.
- Dr. Urte Gayko resigned from Board to focus on her full-time role as Head of Regulatory, Safety, and Quality; resignation not due to any disagreement.

## SEC filing metadata
- accession: 0001599298-22-000109
- form_type: 8-K
- ticker: SMMT
- cik: 0001599298
- company_name: Summit Therapeutics Inc.
- filed_at: 2022-10-03T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1599298/000159929822000109/0001599298-22-000109-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1599298/000159929822000109/smmt-20220928.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001599298-22-000109
- JSON: https://secwatch.observer/filing/0001599298-22-000109.json
- Plain text: https://secwatch.observer/filing/0001599298-22-000109.txt

## Key facts
- Executive change
  Urte Gayko resigned as Director at Summit Therapeutics Inc..
  - Action: resigned
  - Role: Director
  source text: effective September 28, 2022, Urte Gayko resigned from the Board of the Company in order to create a vacancy for Dr. Robert Booth, PhD
  evidence_url: https://www.sec.gov/Archives/edgar/data/1599298/000159929822000109/0001599298-22-000109-index.htm
- Executive change
  Robert Booth was appointed as Director at Summit Therapeutics Inc..
  - Action: appointed
  - Role: Director
  source text: On September 28, 2022, the Board unanimously approved (i) the election of Dr. Robert Booth, PhD as a director
  evidence_url: https://www.sec.gov/Archives/edgar/data/1599298/000159929822000109/0001599298-22-000109-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.